The cash up front across the recent run of biopharma deals was almost shy: twenty, thirty, forty million. The milestone figures ran the other way, a billion here and a billion and a half there, most of it payable only if the science eventually shows up. That was the shape of more than a dozen pacts stacked up over the past couple of weeks, enough that after a while the announcements blur into one long term sheet.
Read them side by side and one more thing separates out: a striking number of the assets kept arriving with the same return address, a Chinese lab. Boehringer Ingelheim signed twice in a single week without a Chinese partner in either deal, so we start with the exception and work toward the rule.
Boehringer's Two-For-One
Boehringer Ingelheim announced two research partnerships in the space of days, both pointed at cancer. The first, a multi-year deal worth $15m, pairs it with Immunai, a New York AI company, to build a data foundation from thousands of patient samples and map the T-cell dysfunction that sits underneath both cancer and immune disease. The argument the partners make is that the two fields share a root cause and have been studied in separate rooms; put the data together and you may find targets neither side saw alone. Immunai has partnered here before, with AstraZeneca and, in January, with Bristol Myers Squibb. The deal, announced June 25, can grow if the science does.
Two days earlier, on June 23, Boehringer signed with Denmark's Combotope to hunt tumor-selective antibodies against glycan-protein targets specific to cancer cells. Combotope runs the discovery on its SMART-Phage platform against a set of oncology targets Boehringer hands over; Boehringer then carries anything that works through development, manufacturing and the market. Terms went undisclosed beyond the familiar shape: upfront cash and research funding for each target, with milestones and royalties stacked behind them.
Where The Assets Came From
Now the rule. The bigger licensing deals shared a common origin. Beijing's Metis TechBio handed US biotech Boulevard Bio global rights to a preclinical trispecific T-cell engager, MTS-128, for $20m up front and up to $1.6bn if it clears every milestone. Shanghai's Abbisko can collect up to about $1.9bn from Lilly across upfront and milestones for drug programs Lilly gets to pick and has not named. Shanghai's Antengene gave Singapore's K2 Therapeutics ex-Greater China rights to a T-cell engager and a second undisclosed program for roughly $20m in upfront and near-term payments on each and up to $960.5m in milestones on each. And Ningbo's TrueLab stands to earn up to $985m from Bionyra Pharma, a Paris and Boston startup that launched the same day, June 22, on a $165m Series A, for two antibodies aimed at inflammatory bowel disease.